Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT06119581
Ignite Creation Date: 2024-05-06 @ 7:44 PM
Last Modification Date: 2024-10-26 @ 3:13 PM
Study NCT ID: NCT06119581
Protocol Section: NCT06119581
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer NSCLC With a Change in a Gene Called KRAS G12C
Official Title: SUNRAY-01 A Global Pivotal Study in Participants With KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression 50 or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum Regardless of PD-L1 Expression
Acronym: SUNRAY-01
Organization: Eli Lilly and Company
Organization Class: INDUSTRY
Organization Study ID: 18612
Secondary IDs
Secondary ID Type Domain Link
2023-503412-33-00 OTHER EU Trial Number None
J3M-MC-JZQB OTHER None None
U1111-1288-0565 OTHER None None
Start Status Module Data
Status Verified Date: 2024-10
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Eli Lilly and Company
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Eli Lilly and Company
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload